

## Subject Index Vol. 84, 2010

- Active surveillance 153  
Adenocarcinoma of the urinary tract 116  
Adjuvant radiotherapy 382  
Adrenal gland 315  
Adult 73  
– urological soft tissue sarcoma 309  
Age 347  
Aging males 424  
Allelic imbalance 461  
American Society of Anesthesiology classification 67  
Anastomotic disruption 436  
Androgen ablation therapy 445  
– deprivation 164  
– receptor 212  
Androgen-regulated genes 203  
Andrology 73  
Angiogenesis 334  
Anterior urethral stricture 78  
Antibacterial therapy 185  
Anti-inflammatory agents 185  
Apoptosis 341, 362, 452  
Axial rigidity 194
- Bacillus Calmette-Guérin 23  
Balanitis xerotica obliterans 78  
Benign prostatic hyperplasia 100, 191, 231, 407, 424  
Bicalutamide 203  
Biochemical failure 382  
Bladder 50, 471  
– cancer 28, 94  
– dysfunction 89  
– neoplasms 14  
Bone marrow mesenchymal cell 94  
Bother 424  
Botulinum toxin 245, 341  
Breakthrough infection 84  
Buccal mucosal graft 78  
Buried penis 10
- Cancer-specific mortality 132  
Carbohydrate antigen 125 116  
– – 19-9 116  
Carcinoembryonic antigen 116  
Carcinoma 50  
Cardiac failure 119  
Cauda equina symptoms 325  
Cavernous tissue 221  
Cell cycle 452  
Cellular viability 452  
[<sup>11</sup>C]choline PET/CT 418  
Chyluria 305
- Citral 100  
Clear cell cancer 292  
Complex penile curvature 275  
Complications 265  
Concealed penis 10  
Cost 45  
C-reactive protein 430  
Cryptorchidism 353  
Cyclooxygenase-2 362  
Cystectomy 14  
Cystitis cystica 239  
Cytology 45
- Dartos flap 265  
Detection rate 147  
Detrusor 341  
Dexmedetomidine 105  
Diabetes 221  
– mellitus 301  
Donor nephrectomy 61  
Doubling time, prostate-specific antigen 159
- Endorectal coil 388  
– – magnetic resonance imaging, sensitivity and specificity 388  
Epidemiology 424  
Erectile dysfunction 194, 221, 407  
Expulsive treatment 254  
Extramedullary plasmacytoma of the ureter 122  
Exulcerating tumor 113
- Fas 362  
*FGFR1* gene 353  
Foreign objects 471  
Functional anatomy 1
- Gemcitabine 23  
Gender reassignment, surgical technique 330
- Gender-transforming surgery, complications 330  
– –, functional/cosmetic outcome 330
- Genetic alteration 461  
Genitourinary surgery 125  
Gil-Vernet 84  
Gleason score 180, 378, 430  
Graft function 61  
– survival 301
- Head injury 89  
Hematoma, subdural 236

- Hemiparesis, contralateral 236
- Hemorrhagic cystitis 467
- High-risk prostate cancer 164
- Hormone-refractory prostate cancer 445
- Human model 226
- Hydrochlorothiazide 319
- Hydronephrosis 122
  - , giant 242
- Hyperbaric oxygen 467
- Hyperthermia 347
- Hypospadias 265
  
- Immunohistochemical markers 292
- Immunosuppression 301
- Immunotherapy 362
- Incidence 73
- Incontinence 236
- Indeterminate lesion 315
- Indolent prostate cancer 440
- Insignificant prostate cancer 153
- Interleukin-6 212
- Intracranial lesions 236
- Irradiation 467
- Ischemia/reperfusion injury 105
  
- Kidney 50
  - cancer 362
  - transplantation 61, 301
  
- Laparoscopy 28, 61
- Left gonadal vein 226
- Leydig cell 347
- Lidocaine suppositories 413
- Ligation 226
- Lingual mucosal graft 78
- Live donation 61
- Living donor nephrectomy 56
- Local staging 388
- Loss of heterozygosity 461
- Lower urinary tract symptoms 89, 231, 325, 424
- Lycopene 400
- Lymph node excision 14
  - - recurrence 418
  - nodes 14
  
- Magnetic resonance imaging 56, 388
- Male 73
- Malignancy 45
- Mass spectrometry 373
- Mast cells 100
- Mathieu repair 265
- Melatonin 452
- Memokath 286
- Metallic stent 286
- Metastatic prostate cancer 159
- Microarray 353
- Microfocal prostate cancer 440
- Military 73
  
- Needle biopsy 180
- Neoadjuvant therapy 479
- Neobladder, complications and prognosis 34
  - , quality of life 34
  - replacement 34
  - types 34
- Neurogenic bladder 89, 369
- Nocturnal enuresis 319
- Nomogram 132
- NSAID-activated gene 1 198
  
- Obstruction, ureteral 286
- Orchialgia 125
- Orthotopic neobladder 34
  - -, long-term follow-up 34
- Overactive bladder syndrome 245
  
- Paclitaxel 116
- Papillary cancer 292
- Patient counseling 40
- Pear-shaped bladder 239
- Pelvic floor 1
  - lipomatosis 239
  - organ malignancies 467
  - pain 400
- Percutaneous biopsy 315
- Performance status 67
- Periprostatic anesthesia 413
  - nerve block 413
- Peyronie's disease 275
- Phosphodiesterase-5 inhibitor 231
- Physical status 67
- Physician-patient dialogue 40
- Pigment epithelium-derived factor 334
- Pilots 73
- Pim1, c-myc 212
- Placebo 319
- Pneumatic lithotripsy 260
- Positive cores 153
- Povidone iodine 305
- Power Doppler imaging 191
- Predictive model 153
- Preputial covering technique 10
- Prognostic factors 67
  - -, prostate cancer 159
- Prolapse 1
- Prostate 341
  - biopsy 141, 185, 378, 395
  - - sepsis 395
  - -, pain control 413
  - cancer 132, 141, 147, 174, 180, 203, 212, 378, 382, 395, 418, 430, 436, 445, 461
    - - biomarker 198
    - - cell lines 452
    - inflammation 185
    - volume 153
  - Prostatectomy 174, 180, 407

- Prostate-specific antigen 141, 159, 185, 378, 430
  - - relapse 418
  - - threshold 141
- Prostatitis 400
- Proteomics technology 373
- Proximal hypospadias 269
- Pyelovesicostomy, laparoscopic 242
- 13q14 461
- Quality of life 424
- Radial rigidity 194
- Radical cystectomy 28
  - prostatectomy 132, 153, 164, 382, 388, 436
- RAF1* gene 353
- Recurrence, carcinoma 50
- 5- $\alpha$ -reductase inhibitors 203
- Renal cancer histology 292
  - cell cancer 119
  - - carcinoma 67, 292, 334, 362, 373, 479
- Repeat biopsy 147
- Residual mass after chemotherapy 113
- Resistive index 191
- Sacral neuromodulation 245
- Sarcoma 309
- Saturation biopsy 147
  - prostate biopsy 440
- Sclerosant 305
- Secondary lymph node surgery 418
- Selenium 400
- Semen parameters 226
- Seminoma 113
- Serenoa repens* 400
- Serotonin 452
- Side effects 119
- Significant prostate cancer 440
- Sirolimus 301
- Soft tissue sarcoma 309
- Somatometrics 73
- SOS1* gene 353
- Steroidogenesis 347
- Stricture, ureteral 286
- Substitution urethroplasty 78
- Sunitinib 119
- Superficial bladder cancer, therapy 23
- Surgical detorsion 105
  - reconstruction 1
  - resection, survival 309
- Tabularized incised plate urethroplasty 265
- Tamsulosin 254
- Testicular pain, chronic 125
  - torsion 105
  - - /detorsion, rats 105
- Testosterone 347
- Thiersch-Duplay procedure 269
- Thioglycolic acid 282
- Thrombospondin-1 221
- TRAIL 445
- Transforming growth factor- $\beta$ 1 221
- Transrectal prostate biopsy 413
  - ultrasonography 191, 395
- Transsexualism 330
- Transurethral resection of prostate 191, 407
- Treatment 260
- Trigonoplasty 84
- Tubularized island flap 269
- Tumor staging 174
  - thrombus 479
- Tunical plication 275
- Type 2 diabetes 301
- Udenafil 231
- Upgrading 378
- Ureter 50
- Ureteral lithiasis, distal 254
  - orifices 84
  - stone 260
- Ureteroscopy 260
- Urethra 471
- Urethral mucosa 282
- Urethroplasty 282
- Urinary diversion, patient's choice 40
  - -, type 40
  - incontinence 1, 369
- Urine 45
- Urodynamic study 89
- Urodynamics 369
- Urothelium 50
- Varicocele 73, 226
- Vascular endothelial cell 94
- Vesico-ureteral reflux 84
- Viral encephalitis 369
- Voiding dysfunction 84, 236, 369
  - function 34
- Voluntary kidney donor 226
- WHO classification of renal tumors 292
- Young cancer patients 292